207 related articles for article (PubMed ID: 29632372)
1. Improving treatment outcome assessment in a mouse tuberculosis model.
Mourik BC; Svensson RJ; de Knegt GJ; Bax HI; Verbon A; Simonsson USH; de Steenwinkel JEM
Sci Rep; 2018 Apr; 8(1):5714. PubMed ID: 29632372
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Rosenthal IM; Zhang M; Almeida D; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2008 Nov; 178(9):989-93. PubMed ID: 18723432
[TBL] [Abstract][Full Text] [Related]
3. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Rosenthal IM; Zhang M; Williams KN; Peloquin CA; Tyagi S; Vernon AA; Bishai WR; Chaisson RE; Grosset JH; Nuermberger EL
PLoS Med; 2007 Dec; 4(12):e344. PubMed ID: 18092886
[TBL] [Abstract][Full Text] [Related]
4. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice.
Zhang M; Li SY; Rosenthal IM; Almeida DV; Ahmad Z; Converse PJ; Peloquin CA; Nuermberger EL; Grosset JH
Am J Respir Crit Care Med; 2011 May; 183(9):1254-61. PubMed ID: 21330452
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Bactericidal Drug Activity and Treatment Outcome in a Mouse Tuberculosis Model Using a Clinical Beijing Strain.
Mourik BC; de Knegt GJ; Verbon A; Mouton JW; Bax HI; de Steenwinkel JEM
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739784
[No Abstract] [Full Text] [Related]
6. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
[TBL] [Abstract][Full Text] [Related]
7. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
[TBL] [Abstract][Full Text] [Related]
8. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
9. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis.
Rosenthal IM; Tasneen R; Peloquin CA; Zhang M; Almeida D; Mdluli KE; Karakousis PC; Grosset JH; Nuermberger EL
Antimicrob Agents Chemother; 2012 Aug; 56(8):4331-40. PubMed ID: 22664964
[TBL] [Abstract][Full Text] [Related]
10. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Jindani A; Harrison TS; Nunn AJ; Phillips PP; Churchyard GJ; Charalambous S; Hatherill M; Geldenhuys H; McIlleron HM; Zvada SP; Mungofa S; Shah NA; Zizhou S; Magweta L; Shepherd J; Nyirenda S; van Dijk JH; Clouting HE; Coleman D; Bateson AL; McHugh TD; Butcher PD; Mitchison DA;
N Engl J Med; 2014 Oct; 371(17):1599-608. PubMed ID: 25337749
[TBL] [Abstract][Full Text] [Related]
11. Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
Park SW; Tasneen R; Converse PJ; Nuermberger EL
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874368
[TBL] [Abstract][Full Text] [Related]
12. Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.
Nuermberger E; Tyagi S; Williams KN; Rosenthal I; Bishai WR; Grosset JH
Am J Respir Crit Care Med; 2005 Dec; 172(11):1452-6. PubMed ID: 16151038
[TBL] [Abstract][Full Text] [Related]
13. Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Tasneen R; Garcia A; Converse PJ; Zimmerman MD; Dartois V; Kurbatova E; Vernon AA; Carr W; Stout JE; Dooley KE; Nuermberger EL
Antimicrob Agents Chemother; 2022 Apr; 66(4):e0239821. PubMed ID: 35315690
[TBL] [Abstract][Full Text] [Related]
14. Interim Guidance: 4-Month Rifapentine-Moxifloxacin Regimen for the Treatment of Drug-Susceptible Pulmonary Tuberculosis - United States, 2022.
Carr W; Kurbatova E; Starks A; Goswami N; Allen L; Winston C
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(8):285-289. PubMed ID: 35202353
[TBL] [Abstract][Full Text] [Related]
15. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
De Groote MA; Gilliland JC; Wells CL; Brooks EJ; Woolhiser LK; Gruppo V; Peloquin CA; Orme IM; Lenaerts AJ
Antimicrob Agents Chemother; 2011 Mar; 55(3):1237-47. PubMed ID: 21135176
[TBL] [Abstract][Full Text] [Related]
17. Intracranial lesion increase under anti-tuberculous therapy.
Alay H; Albayrak A
Rev Soc Bras Med Trop; 2020; 53():e20200112. PubMed ID: 32491102
[No Abstract] [Full Text] [Related]
18. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
Wada M
Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
[TBL] [Abstract][Full Text] [Related]
19. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Gillespie SH; Crook AM; McHugh TD; Mendel CM; Meredith SK; Murray SR; Pappas F; Phillips PP; Nunn AJ;
N Engl J Med; 2014 Oct; 371(17):1577-87. PubMed ID: 25196020
[TBL] [Abstract][Full Text] [Related]
20. Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.
Veziris N; Lounis N; Chauffour A; Truffot-Pernot C; Jarlier V
Antimicrob Agents Chemother; 2005 Oct; 49(10):4015-9. PubMed ID: 16189074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
